Daily Roundup

EOS.ASX PWH.ASX EYE.ASX RPL.ASX BTR.ASX

EOS Transforms into Integrated Counter-Drone Provider with MARSS Acquisition

Electro Optic Systems Holdings Ltd (EOS) is making a strategic move to become a leading integrated counter-drone systems provider. The company has announced the acquisition of MARSS, a Europe-based defense and security technology firm.

MARSS' proprietary NiDAR C2 technology provides advanced AI-enabled decision-making and sensor-effector orchestration to rapidly counter asymmetric drone threats. This acquisition allows EOS to transform from a component supplier to an end-to-end solutions provider, enhancing its capabilities, market reach, and growth potential.

The deal brings MARSS' proven technology, customer contracts, intellectual property, and personnel into the EOS fold. This creates a compelling offering that can compete for larger, higher-value counter-drone programs as a prime contractor. Importantly, the acquisition also expands EOS' geographic footprint and broadens its end-market presence in defense, homeland security, and civil domains.

PWR Secures Ongoing Aerospace and Defense Orders

In other news, PWR Holdings Limited (PWR) has secured a US$9.1 million (~A$13.5 million) follow-on contract to supply advanced cooling solutions for a US government project. This contract builds on the successful delivery of PWR's previous order, reinforcing the company's position as a leader in aerospace and defense applications.

The new contract is expected to be delivered predominantly in FY 2027, supporting PWR's growing reputation for reliable execution and adaptability on complex projects. The US government project is scheduled to extend over multiple years, subject to forecasted demand, funding, and PWR's performance.

Nova Eye Medical Reports Record Sales

Nova Eye Medical Ltd (ASX: EYE) has delivered a standout performance, reporting record global sales of US$6.1 million for the December 2025 quarter. This represents a 38% increase on the prior corresponding period and a 25% improvement on the previous quarter.

The company's six-month sales of US$10.9 million were up 29% year-on-year, while the last twelve months saw global sales reach approximately US$21 million (A$32.2 million) - a 24% increase on the prior twelve months and three times the industry growth rate.

The strong results reflect continued demand for Nova Eye's iTrack technology, which has now been used in around 180,000 surgical cases worldwide. The minimally invasive, rejuvenative approach is gaining recognition among more surgeons as the company's commercial efforts continue to pay off.

Regal Partners Expects $145 Million NPAT in 2025

Regal Partners Ltd (ASX:RPL) has provided an upbeat outlook, forecasting normalised net profit after tax (NPAT) of approximately $145 million for the 2025 calendar year. This performance is underpinned by strong results across the firm's investment strategies, with 2H25 performance fees anticipated to be around $130 million.

Regal's funds under management (FUM) also rose to approximately $20.8 billion as at 31 December 2025, with net inflows of $80 million for the quarter and $1.5 billion for the full year. The company will provide further details on flows and FUM in its upcoming quarterly update and 2025 results announcement.

Brightstar Upgrades Lord Byron Mineral Resource

Rounding out the day's news, Brightstar Resources Ltd has reported positive results from reverse circulation (RC) drilling at its Lord Byron deposit, part of the Goldfields Hub project. The drilling identified high-grade intercepts of up to 24.7g/t Au, leading to a 6% increase in the Mineral Resource Estimate to 267koz of gold.

Brightstar plans to focus its 2026 exploration efforts on targeting the lode along strike to the south and at depth, as well as testing early-stage targets for comparable mineralization beneath shallow cover. The company continues to advance the Goldfields Hub towards a final investment decision in the first quarter of 2026.